Fulcrum Therapeutics Announces Proof-of-Concept for FTX-6058 in Sickle Cell

  Achieved up to 6.3% hemoglobin F (HbF) induction in initial subjects in first cohort; HbF was increasing at last measured timepoint

- Supports proof-of-concept that FTX-6058 is a novel oral HbF inducer

- FTX-6058 was generally well tolerated; no serious treatment emergent adverse events (TEAEs) reported

- Data to be presented as a poster at European Hematology Association (EHA) Hybrid Congress; highlights to be presented at the Foundation for Sickle Cell Disease Research Symposium (FSCDR) on June 11, 2022

- Fulcrum to review results during an investor conference call, including guest KOL Dr. Julie Kanter, at 8:00 a.m. ET today

Conference Call Information 
Fulcrum will host a conference call and webcast today at 8:00 am ET to discuss these results. The webcast will be accessible through the Investor Relations section of Fulcrum’s website at www.fulcrumtx.com. Following the live webcast, an archived replay will also be available. 

Dial-in Number 
U.S./Canada Dial-in Number: (800) 527-6973 
International Dial-in Number: (470) 495-9162 
Conference ID: 4477738 

Replay Dial-in Number: (855) 859-2056 
Replay International Dial-in Number: (404) 537-3406 
Conference ID: 4477738 

https://www.globenewswire.com/news-release/2022/06/10/2460410/0/en/Fulcrum-Therapeutics-Announces-Proof-of-Concept-for-FTX-6058-in-Sickle-Cell-Disease-Based-on-Initial-Data-from-the-Ongoing-Phase-1b-Trial.html